Avid cuts revenue guidance

 -- Recorded Second Quarter Revenue of $25.4 Million --

-- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million --

-- Entered into Partnership with California Institute of Regenerative Medicine (CIRM) to Advance Manufacturing of Adeno-Associated Adenovirus, as well as Other Cell and Gene Therapy Programs –

-- Completed Construction of Cell and Gene Therapy Facility; Grand Opening Scheduled for January 2024 --

-- Adjusting Fiscal 2024 Revenue Guidance to $137 to $147 million --

https://www.globenewswire.com/news-release/2023/12/07/2792891/0/en/Avid-Bioservices-Reports-Financial-Results-for-Second-Quarter-Ended-October-31-2023.html